Effect of cyclin-dependent kinase 4 and 6 inhibitors (CDKIs) on body composition (BC) in patients (pts) with hormone receptor-positive, HER2-negative (HR+/HER2-) metastatic breast cancer (MBC).

Lisa Phuong,Janki Patel,Nadia Baka,Jessica Goldman,Michael Lyudmer,Stephanie Shamir,Junwen Deng,Alvaro Alvarez Soto,Jesus Del Santo Anampa Mesias

Effect of cyclin-dependent kinase 4 and 6 inhibitors (CDKIs) on body composition (BC) in patients (pts) with hormone receptor-positive, HER2-negative (HR+/HER2-) metastatic breast cancer (MBC).

2021

Lisa Phuong
Janki Patel
Nadia Baka
Jessica Goldman
Michael Lyudmer
Stephanie Shamir
Junwen Deng
Alvaro Alvarez Soto
Jesus Del Santo Anampa Mesias

e13033Background: CDKIs with endocrine therapy (ET) is first-line treatment in HR+/HER2- MBC. Mouse models have shown that CDKIs prevent pRB phosphorylation in the mediobasal hypothalamus, a pathwa...

Keywords:

endocrine therapy
Medicine
mediobasal hypothalamus
in patient
Hormone receptor
HER2 negative
Metastatic breast cancer
Cancer research
Cyclin-dependent kinase 4
Phosphorylation

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations